在心力衰竭中使用Vericiguat,减少喷射率:希望还是坚实的现实?
Michele Correale1, Giuseppe Pelaggi2, Maria Concetta Catanoso2
1Cardiothoracic Department, Policlinico Riuniti University Hospital, Foggia, Italy. michele.correale@libero.it.
Heart failure reviews
|July 23, 2024
概括
作为一种可溶性 guanylate cyclase 刺激剂的 vericiguat 在减少心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者 它可以作为HFrEF治疗的第五支柱,特别是对于那些患有并发症的人来说.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 最近心力衰竭的进展与减少喷射分数 (HFrEF) 治疗,包括RNAI和SGLT2抑制剂,改善了患者的治疗结果.
- 尽管取得了这些进展,但HFrEF患者仍然存在显著的残留风险.
- 维里西瓜特是一种口服可溶性 guanylate cyclase (sGC) 刺激剂,向NO-sGC-cGMP通路,以减少氧化应激和内皮功能障碍.
研究的目的:
- 在HFrEF中审查关于 vericiguat的随机临床试验,副研究和元分析.
- 评估 vericiguat作为HFrEF治疗的第五个支柱的潜在作用.
- 为了确定关于 vericiguat 的有效性和应用的现有证据缺口.
主要方法:
- 随机临床试验,副研究和对 HFrEF 患者的 vericiguat 的元分析的综述.
- 对维多利亚试验数据的分析表明, vericiguat对心血管死亡率和心力衰竭住院治疗的影响.
- 检查 vericiguat在患者亚组中的疗效,包括患有功能衰竭等并发症的患者.
主要成果:
- 维多利亚试验显示,心血管死亡率和心力衰竭再住院治疗的复合性心血管死亡率减少了10%,与 vericiguat.
- 韦里西瓜特显著减少了心力衰竭住院的情况.
- 韦里西瓜特在那些不能耐受标准HFrEF治疗的并发病患者中显示出治疗价值.
结论:
- 韦里西瓜特显示出作为HFrEF治疗的第五支柱的潜力,提供超越当前疗法的好处.
- 目前的指导方针建议 vericiguat作为症状HFrEF患者的第二线治疗,尽管治疗优化.
- 需要进行进一步的研究,以澄清剩余的证据缺口,并充分确定受访者在HFrEF管理中的作用.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
414
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
414
01:26Heart Failure Drugs: Inotropic Agents
559
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
559
01:22Heart Failure Drugs: Diuretics
356
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
356
01:22Heart Failure Drugs: β-Blockers
333
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
333
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
150
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
150
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
683
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
683